A therosclerotic vascular disease is the leading cause of mortality in the Western world. Abnormal proliferation of vascular smooth muscle cells (VSMCs) plays an important role in atherogenesis and restenosis after angioplasty or stenting. 1 Agents that inhibit the proliferation of VSMCs are of considerable therapeutic importance for the treatment of cardiovascular diseases. This is particularly the case for in-stent restenosis, the incidence of which has been reduced dramatically by the widespread use of stents that elute cell proliferation-inhibitory drugs. However, the incidence of in-stent thrombosis remains a significant clinical problem 2 given the potentially life threatening consequences of a thrombotic event. The endothelium plays a crucial role in the prevention of in-stent thrombosis, with delayed reendothelialization likely responsible for late stent thrombosis. 3 Most conventional, orally administered, drugs have failed to inhibit restenosis in humans following coronary angioplasty and stenting, 4 -6 one exception being probucol, a rarely used lipid-lowering drug with antiinflammatory and antioxidant properties. 7 Probucol has also been reported to inhibit experimental in-stent thrombosis. 8 These beneficial effects are associated with promotion of endothelial cell growth and enhancement of reendothelialization and inhibition of VSMC proliferation. 9 Recent evidence suggests that the mechanisms of probucol and related compounds to inhibit VSMC proliferation, as well as experimental restenosis and atherosclerosis, are mediated via induction of the enzyme heme oxygenase (HO)-1. 10, 11 HO-1 is the inducible of 2 forms of heme oxygenases that degrade heme to CO, Fe 2ϩ , and biliverdin, which is then reduced to bilirubin by biliverdin reductase. 12 HO-1 is increasingly recognized as an important mediator of cellular homeostasis in conditions of stress and injury. A vast number of agents and conditions including heme, tert-butylhydroquinone (tBHQ), hypoxia, oxidative stress, or UV irradiation stimulate HO-1 expression, primarily at the transcriptional level. 13 HO-1 plays a crucial role in cell survival and in the control of cell growth in vascular diseases. 14 Like its pharmacological induction, adenovirus-mediated overexpression of HO-1 inhibits the proliferation of VSMCs and protects against experimental atherosclerotic diseases, 15 whereas overexpression of HO-1 promotes growth of coronary artery endothelial cells. 16 This differential effect of HO-1 on cell cycle progression is thought to be mediated by the HO-1 reaction product CO. 17 The HO-1-induced opposing effect on the growth of VSMCs versus endothelial cells is reminiscent of the effect of the transcription factor Yin Yang (YY)1. 18 YY1 (also known as ␦, NF-E1, UCRBP, and CF1) is a ubiquitous and multifunctional zinc-finger transcription factor. 19 It is a member of the polycomb group protein family, a group of homeobox gene receptors that play critical roles in hematopoiesis and cell cycle control. YY1 regulates the expression of genes important in DNA replication, protein synthesis, and cellular responses to external stimuli during cell growth and differentiation. This regulation of gene expression is based on the ability of YY1 to initiate, activate, or repress transcription depending on the context. 19 Overexpression of YY1 significantly inhibits VSMC proliferation in vitro and in vivo. 20 Based on the similar functional properties of HO-1 and YY1 related to the growth of vascular cells, we explored whether YY1 mediates the antiproliferative effect of HO-1 in VSMCs. Here we show, for the first time, that induction of HO-1 leads to the expression of YY1 and that there is a close interaction between HO-1 and YY1 function.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org and includes information regarding the following: materials used in the study, rat aortic smooth muscle cells (RASMCs), RNA isolation and real-time quantitative PCR, isolation of total cell extracts, Western blotting, and heme oxygenase activity.
Vascular Injury, Intimal Hyperplasia, and Immunohistochemistry
Rabbit aortic balloon injury was performed as described previously, 9 with approval from the University of New South Wales Animal Ethics Committee. Rat carotid balloon injury was performed and the extent of intimal hyperplasia was assessed as described previously, 11 with approval from the University of Sydney Animal Ethics Committee (see Online Data Supplement for more details). For immunohistochemistry, see the Online Data Supplement.
HO-1 and YY1 Overexpression and Knockdown
The preparation of the HO-1 overexpression construct is described in the Online Data Supplement. Where indicated, YY1 was transiently overexpressed using plasmid pCB6 ϩ -YY1, with pCB6 ϩ serving as a control vector. 21 Plasmids were purified by CsCl gradient and used for transient transfection of RASMCs using FuGENE 6 (Roche Diagnostics). To knockdown HO-1 and YY1, stealth RNAi duplexes (Invitrogen) were used to transiently transfect RASMCs using X-treme GENE transfection reagent (Roche Diagnostics) (see Online Data Supplement).
Statistical Analysis
Data represent averaged results from 3 to 6 separate experiments as indicated, with error bars indicating SEM unless stated otherwise. Statistical significance was assessed using the Wilcoxon Mann Whitney Rank Sum test, with PϽ0.05 considered significant.
Results

Probucol Decreases Neointimal Formation in Response to Injury in Part via Increasing Medial Expression of YY1
We reported previously that oral administration of probucol effectively attenuates balloon injury-induced intimal hyperplasia in the abdominal aorta of rabbits and in the common carotid artery of Zucker rats by increasing HO-1 expression and heme oxygenase activity. 11 Similarly, probucol treatment increased medial expression of HO-1 in the carotid artery of Sprague-Dawley rats 4 days after injury ( Figure 1A) , a time point shown previously to coincide with maximal HO-1 expression. 10 At the same time, medial expression of the zinc-finger transcription factor YY1 was also observed, and this too was increased by probucol in both the abdominal aorta of rabbits (Online Figure I ) and the carotid artery of rats ( Figure 1B) . These results suggest that in these models, probucol induces the expression of both HO-1 and YY1 in medial cells following vascular injury.
To assess the potential functional relevance of this coexpression, we examined the impact of YY1 knockdown on the ability of probucol to inhibit intimal thickening. Initial pilot studies carried out in Sprague-Dawley rats confirmed that topical application of YY1 small interfering (si)RNA in pluronic gel to the artery at the time of injury was effective in decreasing subsequent YY1 expression in medial cells even at 2 weeks after injury (Online Figure II We next investigated whether mitogen-activated protein kinase (MAPK) signaling was involved in the HO-1-mediated expression of YY1 in RASMCs, using tBHQ as a model agonist. Blocking extracellular signal-regulated kinase (ERK) had no effect on HO-1 or YY1 expression (Online Figure IV) . In contrast, inhibition of c-Jun N-terminal kinase (JNK) phosphorylation attenuated, whereas inhibition of p38 kinase, augmented HO-1 and YY1 induction (Online Figure IV) . Similar results were obtained in RASMCs transfected with human HMOX1 cDNA (data not shown). These data suggest that JNK positively and p38 negatively regulates HO-1 induction in RASMCs by tBHQ and that both signaling paths are upstream of HO-1. The observation that expression of YY1 mirrored that of HO-1 in these experiments lends further credit to the notion that HO-1 induction is linked closely to YY1 expression. We next examined the effect of YY1 expression on HO-1 levels. Transient transfection of RASMCs with YY1 using plasmid pCB6
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ϩ -YY1 21 resulted in increased HO-1 protein (Online Figure V) , indicating that HO-1 and YY1 may amplify the expression of each other, thereby enhancing the biological effect.
HO-1-Mediated Expression of YY1 is Dependent on Heme Oxygenase Enzyme Activity and CO
HO-1 protein has recently been reported to be localized to the nucleus of cells exposed to hypoxia, and to mediate activation of transcription factors independent of its enzymatic activity. 22 In the case of RASMCs treated with probucol, however, HO-1 activity was required for the increased YY1 expression. Thus, tin-protoporphyrin-IX (SnPP) (a pharmacological inhibitor of heme oxygenase) completely abrogated the ability of probucol to increase YY1 ( Figure 5A ), whereas the inhibitor did not block HO-1 protein expression. Control experiments confirmed that SnPP completely blocked the increase in heme oxygenase activity seen in RASMCs treated with probucol (Online Figure VI) .
HO-1-mediated induction of YY1 is likely dependent on CO generated as a product of HO-1 enzyme activity. This is because the inclusion of hemoglobin, which avidly binds CO, completely blocked the ability of tBHQ to induce YY1 in RASMCs, without materially affecting the expression of HO-1 ( Figure 5B) . Conversely, addition of the CO-releasing molecule, tricarbonyldichlororuthenium (II) dimer (CORM2), increased YY1 protein ( Figure 5C ).
Inhibition of RASMC Proliferation by HO-1 Is Dependent on YY1
A phenotypic manifestation of VSMCs treated with probucol or related compounds is HO-1-dependent inhibition of cell growth. 10, 11 We confirmed this property of probucol for RASMCs, using serum inducible bromodeoxyuridine incorporation as the read-out ( Figure 6A ). Similar to the situation with HO-1, knockdown of YY1 abrogated the ability of probucol to inhibit RASMC growth, irrespective of whether cell proliferation was assessed by bromodeoxyuridine incorporation ( Figure 6B ) or by cell counting (data not shown). Effective knockdown of HO-1 and YY1 by the respective siRNA was confirmed by Western blot (data not shown). Similar results were obtained with RASMCs that expressed human HO-1 as a result of adenovirus-mediated transfection. Compared with the corresponding LacZ-transfected control cells, RASMCs expressing HO-1 grew slower ( Figure 6C ), and this growth inhibition was abrogated significantly by YY1 siRNA but not YY1 scRNA ( Figure 6D ). In contrast to RASMCs, adenoviral transfection with HMOX1 had no material effect on the growth of bovine aortic endothelial cells (Online Figure VII) despite efficient HO-1 protein expression (Online Figure VII, inset ). These data demonstrate that HO-1-mediated induction of YY1 expression is functionally related to the control of RASMCs but not bovine aortic endothelial cell growth. Furthermore, the results suggest that there may be species and/or vascular bed-specific differences with regard to the growth effect of HO-1, given the earlier finding by others that overexpression of human HO-1 promoted the growth of rabbit coronary endothelial cells. 16 
Discussion
The present study shows that an increase in cellular HO-1 is associated with the enhanced expression of the zinc-finger transcription factor YY1 and that this is both dependent on enzymatic activity of HO-1 and functionally important with regard to the impact of HO-1 on the proliferation of VSMCs. These observations may help explain the antirestenotic and antiatherosclerotic activities of HO-1 and pharmacological inducers of this enzyme. Several lines of evidence support the concept that the multifunctional transcription factor YY1 is a down-stream effector of HO-1. Thus, independent of whether expression of HO-1 was achieved through pharmacological or molecular means, its transcript always increased before that of YY1.
Also, blockade of HO-1 enzymatic activity, as well as addition of hemoglobin to scavenge the reaction product CO, completely abrogated the increase in YY1 expression, without measurably lowering the extent of HO-1 protein induction. In addition, chemically generated CO alone was able to increase YY1 protein expression. Interestingly, however, overexpression of YY1 also increased HO-1 protein, suggesting that the interaction between the 2 proteins is complex and may involve a feed forward amplification. In any case, the fact that knockdown of YY1 effectively abrogated the ability of probucol to inhibit intimal hyperplasia provides direct evidence that the interaction between HO-1 and YY1 is functionally important in vivo.
Our findings extend existing knowledge of how induction of HO-1 may translate into cellular effects via the transcription factor YY1. By modulating cellular heme levels, heme oxygenase activity can regulate the transcription factor Bach1, a heme-binding protein that negatively regulates the expression of genes involved in heme metabolism, oxidative stress and globin synthesis, 23, 24 including HO-1. Such HO-1/ heme-dependent regulation of the transcription factor Bach1 is conceptually different from the HO-1-mediated expression of YY1 reported here, because YY1 is not known to avidly bind heme. A previous study reported hypoxia-or hemeinduced nuclear entry of a C-terminally cleaved form of HO-1 to be associated with activation of oxidant-responsive transcription factors including activator protein-1. 22 In that study, however, activation of transcription factors was independent of enzymatic activity of HO-1, 22 whereas the HO-1-induced expression of YY1 described here required enzymatic activity. Other previous studies reporting altered expression of transcription factors used the heme oxygenase reaction product CO as a pharmacological agent rather than studying the effects of cellular HO-1 activity. Examples of such factors include hypoxia-inducible factor-1, 25-27 peroxisome proliferation-activated receptor-␥, 28 early growth response-1, 29 and E2F1. 30 Downregulation of E2F1 or E2F3 inhibits the proliferation of SMCs. 31 YY1 is a partner protein for several members of the E2F transcription factor family. 32 E2F and YY1 binding sites in the promoter of Cdc6 are important for Cdc6 activation and regulation of G 1 /S phase transition by E2F2 or E2F3, although E2F1 does not appear to interact with this promotor, 33 and we are unaware of any previous reports on E2F1/YY1 interactions.
To date, there has been only circumstantial evidence pointing toward a possible regulatory link between HO-1 and YY1. Serum deprivation decreases HO-1 in cultured astrocytes 34 and YY1 in NIH3T3 cells. 35 Conversely, serum repletion of RASMCs increases HO-1 36 and augments HO-1 and YY1 expression (our unpublished data). Also, experimental ER stress induces HO-1 in VSMCs 37 and YY1 in human umbilical vein endothelial cells, 38 and both proteins have been reported to be involved in the protection of cells against ER stress. 37, 39 The present observation that HO-1 inhibits VSMC proliferation via YY1 also extends the known functional connection between the 2 proteins. HO-1 is a key enzyme involved in the reutilization of body iron, making it available for erythropoiesis. 40 HO-1 is primarily responsible for the degradation of hemoglobin heme of aged red cells that are removed from the circulation by macrophages of the reticuloendothelial system. The iron generated by the action of HO-1 is released to transferrin, transported to the bone marrow, and reused in de novo synthesis of heme. The resulting heme controls the expression of globin genes in erythrocyte progenitor cells of the bone marrow, and hence erythropoiesis. 40 Interestingly, globin expression is also regulated by YY1, and this plays an important role in globin switching during development. YY1 regulates the expression of the ␣ 41,42 and ␤ 43 globin clusters, while repressing the expression of embryonic globin. 44 In addition, YY1 controls body iron homeostasis by modulating the expression of the transferrin receptor on endothelial cells, 45 a process intimately linked to cellular uptake of iron.
We show here that HO-1 activity is required, and the heme oxygenase reaction product CO responsible for, the upregulation of YY1 expression. This suggests an involvement of CO in the cellular signaling that links HO-1 with YY1. Because there is precedence for CO regulating the expression of a transcription factor via ERK, 29 we asked whether MAPK signaling was involved in the increase of YY1 by HO-1. Indeed, our results suggest that p38 negatively and JNK positively regulates HO-1 induction by tBHQ in RASMCs. These results agree with previous findings reporting p38 to negatively regulate tBHQ-mediated induction of other genes containing antioxidant response elements in their promoter regions, irrespective of the cell type involved. 46, 47 In contrast to our results obtained in RASMCs, JNK activation does not appear to be involved in tBHQ-induced gene induction in other cell types. 47, 48 The role of ERK in tBHQ-induced transcriptional activation seems to be cell-specific, because ERK is a negative regulator in H4IIE cells 48 and a positive regulator in Hepa1c1c7 cells. 49 Irrespective of this, our studies with the MAPK inhibitors provide a separate line of evidence in support of an interdependence of HO-1 and YY1.
Pharmacological induction of HO-1 or overexpression of HO-1 inhibits VSMC proliferation in vivo 11, 15 and in vitro. 10, 50 This is most commonly attributed to CO production, 30, 36 although bilirubin/biliverdin have also been reported to inhibit VSMC growth. 51 In VSMCs, CO can activate soluble guanylate cyclase, leading to increased cGMP, 52 activation of p38 MAPK, and induction of the cell cycle inhibitor p21 Waf1/Cip1 . 53 CO also selectively inhibits the expression of cyclin A and markedly decreases the phosphorylation of retinoblastoma, 36 ie, processes that contribute to the inhibition of cell cycle progression. In apparent contrast, inhibition of VSMC growth by YY1 overexpression has been reported to repress p21 Waf1/Cip1 , preventing the assembly of the p21 Waf1/Cip1 -cdk4 -cyclin D1 complex and thereby blocking phosphorylation of retinoblastoma protein. In light of our finding that HO-1 induction increases YY1 and that both proteins are involved in mediating the antiproliferative effect on RASMCs, further studies are warranted to clarify the involvement of p21 WAF1/Cip1 along the HO-1/YY1 axis.
It remains unknown how HO-1 overexpression or pharmacological HO-1 induction exerts cell type-specific inhibition or enhancement of cellular proliferation. However, our present study suggests that YY1 is intimately linked to the actions of HO-1 and, as such, may affect functions in addition to the control of cell growth.
